MMP19 is a matrix metalloendopeptidase that degrades extracellular matrix components including aggrecan, collagen type IV, laminin, and fibronectin 1. Beyond canonical ECM degradation, MMP19 exhibits context-dependent pathological and protective roles across multiple disease contexts. In pulmonary fibrosis, MMP19 demonstrates antifibrotic activity in murine models 1, yet endothelial cell-derived MMP19 promotes disease progression by inducing endothelial-to-mesenchymal transition (EndoMT) and monocyte infiltration via interactions with SDF1 and Endothelin-1 2. In thoracic aortic aneurysm and dissection (TAAD), MMP19 plays a protective role: Mmp19 deficiency exacerbates aortic pathology by promoting aggrecan accumulation and VSMC phenotypic switching through Wnt/β-catenin signaling, and MMP19 restoration mitigates disease progression 3. In cancer, IL-17 upregulates MMP19 through STAT3-K631 acetylation by p300, enhancing NSCLC cell migration and invasion 4. Similarly, MMP19 cooperates with GPSM1 to promote colorectal cancer proliferation and EMT 5. Regarding ocular pathology, MMP19 localization to optic nerve septa and its dysregulation is implicated in cavitary optic disc anomalies, with potential relevance to glaucomatous optic disc cupping 6.